Malaria Diagnostics Market (By Technology: Molecular Diagnostic Tests [Real-Time PCR (qPCR), Conventional PCR], Rapid Diagnostic Tests, Microscopy) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

The global malaria diagnostics market is expected to grow at noteworthy CAGR around 5.9 % throughout the forecast period 2019 to 2026 and reach around US$ 900 million by 2026.

Malaria is triggered by the Plasmodium parasites and the female anopheles mosquito transmits them. Malaria diagnosis involves microscopy and blood testing. The WHO estimated 203 million cases of malaria in 2012 to lead to an estimated 627,000 fatalities. There were 33 million instances of malaria, respectively. Accurate and early malaria diagnoses are essential because patients quickly recover when early therapy is begun and investment in diagnostic methods is stimulated. This has resulted to technological progress in developing fast diagnostic testing and is the main driver for this market's growth. The difficulties confronting this market are to speed up diagnostic test recognition and use in malaria diagnosis. WHO has updated its Malaria Guidelines and is recommending that all suspected malaria instances have been tested. Global partners ' initiatives to provide universal access to diagnostic kits have been conducted.

The report provides analysis of global Malaria Diagnostics market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Dynamics

Advanced technology has changed the diagnosis of paludism and is highly sought after. Through these trials antigens of malaria parasites have been detected successfully. The demand for malaria diagnostics on the market is expected to increase with increased public financing for the healthcare industry and increased investments in research and development of new therapies. QBC method, peripheral blood streams and serological tests are among the most prevalent methods used to detect malaria. In addition, the medicines used most frequently in the therapy of malaria include atovaquone-proguanil (Malarone), artemether-lumefantrain (Coartem), clindamycin and quinidine. Also evaluated are the factors affecting demand in the drug classes. The study also examines the effect on the world malaria diagnostics industry of the imminent patent expiry of blockbuster drugs. On the other hand, a number of frequently used diagnostic techniques could limit the development of the market to some extent by technological problems.

Market Insights

The market is driven by increased demand for malarial diagnostics and new diagnostic methods. Malaria is one of the largest lifelong threats, usually happening through changing climates, low economic growth, underdeveloped health infrastructure, as well as a absence of access to sophisticated therapy, in tropical and subtropical areas.

In the 2017 World Health Organization (WHO), over 4,35,000 people died of the Tropical Disease Caused from the infection of the female anopheles mosquito with Plasmodium species worldwide. Data from the same source show that over 219 million malaria instances have been registered worldwide, with over 92% from Africa, 6% from Southeast Asia and 2% from the Eastern Mediterranean. The increasing incidence of diseases is therefore also expected to increase future market growth.

In many African, Asian and Latin American nations like Uganda, the Democratic Republic of Congo, Columbia, Peru and India, the latter are the major causes of death. Malaria can lead to low birth weighs, dead births and congenital infections during pregnancy. One of the main market drivers is also anticipated to be technological progress. Increasing demand and increased demand for high-grade and cost-effective diagnostic techniques can lead to improvements in access to diagnostics in distant fields in particular. Heavy investments by government and private investors to reduce the incidence of the disease are also a key driver of the economy. According to WHO data, in 2017, some USD 3.1 billion was invested by private global investors as well as government authorities in the endemic countries in controlling and eliminating this disease. Globally, more than 312 million quick trials were performed, most of them in WHO Africa, the worst-affected region.

Technology Stance

Due to intermittent use of the disease diagnostic method, microscopy was the second largest segment. It is one of the most traditional and reliable disease diagnostic techniques. It is estimated by the WHO that more than 204 million microscopic malarial tests are performed worldwide.

This technique can identify malaria parasites in several phases of life including P. falciparum, P. ovale malariae, P. and P. vivax. Furthermore, the density of the parasite can also be quantified according to the design plan. The most rapid development in the forecast period due to precise diagnosis provided by these exams is anticipated in the molecular test section.

Molecular diagnostic tests include standard PCR and quantitative or real-time (qPCR) polymerase chain reaction. qPCR was used to identify low parasite levels and blended diseases with DNA obtained from blood samples. These tests are exact, extremely sensitive and able to detect small numbers of parasites. However, due to high expenses and absence of dedicated laboratories and qualified personnel, the market share of such exams is less significant.

Regional Stance

Due to the greatest burden of disease, Africa is anticipated to lead the market. The most common malaria parasite in the area, P. falciparum, is estimated to account for 99% of all African instances. It is estimated that 92% of worldwide malaria instances were registered in this area and 93% of worldwide malaria fatalities. These facts show that malaria is increasing in Africa.
The second biggest proportion of the national economy is projected to occupy the Southeast Asian market. The tests for the diagnosis of diseases are mainly resulted by microscopy tests in India in terms of quantity. The need for diagnostic control and care-based surveillance systems is projected to improve with growing awareness of the illness, and the private sector financing, thus driving market growth.

Market Segmentation

Global Malaria Diagnostics Market, By Technology

• Molecular Diagnostic Tests
• Real-Time PCR (qPCR)
• Conventional PCR
• Rapid Diagnostic Tests
• Microscopy

Global Malaria Diagnostics Market, By Geography

• North America.
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

The market research study on “Malaria Diagnostics Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Malaria Diagnostics market segments with market dynamics and their impact. The report also covers basic technology development policies.

This study offers an assessment of the recent business trends in each subsegment from 2015 to 2026 and forecasts income and volume growth in the worldwide, regional and nation levels. ARC segmented the worldwide report for malaria diagnostics based on technology and region for this research:

The buyer's negotiating power on this market is high according to Porter's five-force model, as many providers produce diagnostic kits. It analyzes the threat to this industry from replacements and fresh entrants. The market for malaria diagnostics is growing as a result of worldwide efforts to decrease fatalities caused by this disease. The study outlines governments ' attempts to use diagnostics in a widespread manner. The main investment areas are evaluated on the basis of this market's future growth potential.

Key Players & Strategies

Some of the main businesses include bioMérieux; Beckman Coulter, Inc.; Access Bio., Inc. Sysmex Partec GmbH; Abbott Laboratories; Nikon Corporation; Siemens Healthineers; and Olympus Corp. Their large worldwide presence and distribution channels are responsible, in specific, for Abbott; bioMérieux; Siemens Healthineers; Beckman Coulter Inc.; Leica Microsystems GmbH; and Bio-Rad Laboratories, Inc. For example, bioMérieux has a vast network of retailers across 42 diagnostic solutions in more than 150 nations.